Anchiano Therapeutics
Targeted Cancer Therapies Based on H19 Gene
Company Overview
Snapshot
Founded in October 2004 by Prof. Avraham Hochberg, Anchiano Therapeutics operated with 1–10 employees. The company raised $37.7 million across 6 funding rounds from 2 investors. In March 2021, Anchiano Therapeutics completed a merger with Chemomab Therapeutics.
Business overview
Anchiano Therapeutics was a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for cancer-related diseases. The company's core product candidates included BC-819, developed for non-muscle-invasive bladder cancer, and BC-821, a second-generation drug for systemic treatment of advanced malignant neoplasms. Anchiano Therapeutics operated within the Health Tech & Life Sciences sector, specifically focusing on Pharmaceuticals and Medical Treatment & Therapeutics, serving markets in Japan, Europe, and the United States.
Strategic signal
In March 2021, Anchiano Therapeutics completed its merger with Chemomab Therapeutics. This strategic move indicates a significant shift in the company's operational structure and future direction, signaling to investors a consolidation within the biopharmaceutical landscape and a potential for combined therapeutic pipelines.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant corporate event for Anchiano Therapeutics in March 2021?
- In March 2021, Anchiano Therapeutics completed its merger with Chemomab Therapeutics, marking a major strategic consolidation for the company.
- When did Anchiano Therapeutics announce shareholder approval for its merger with Chemomab and private financing?
- In March 2021, Anchiano Therapeutics announced shareholder approval for the merger with Chemomab and priced a $45.5 million private financing.
- What was the outcome of Anchiano Therapeutics' Nasdaq IPO in February 2019?
- In February 2019, Anchiano Therapeutics announced the pricing of a $30.5 million Initial Public Offering on Nasdaq, though its stock subsequently fell.
- When did Anchiano Therapeutics change its name from BioCancell?
- In August 2018, BioCancell announced its company name change to Anchiano Therapeutics.
- What was a key development for Anchiano Therapeutics in January 2018?
- In January 2018, Anchiano Therapeutics (then BioCanCell) raised $25 million with plans to seek a U.S. listing.